Parkin, a protein associated with Parkinson's disease found to be elevated in individuals infected with COVID-19!

Medical News: A recent study conducted by researchers from the National Research Center for Preventive Medicine (NRCPM) in Moscow, Russia, has revealed a surprising link between the protein Parkin, commonly associated with Parkinson's disease, and COVID-19 infection. This Medical News report uncovers the elevated levels of Parkin found in patients with COVID-19 and explores its potential implications for neurodegenerative diseases.


Parkin, a protein associated with Parkinson's disease found to be elevated in individuals
infected with COVID-19!

COVID-19, caused by the SARS-CoV-2 virus, is known for its wide array of health impacts, including long-lasting effects that persist even after the virus is no longer active in the body. The study findings demonstrate that COVID-19 affects protein profiles and the potential consequences on neurological health.
 
Background of the Study
The primary aim of the study was to investigate the impact of COVID-19 on the serum protein profile of individuals. The researchers utilized an antibody array technology to analyze the serum of patients who had tested positive for SARS-CoV-2 antibodies and those who had not. Among the various proteins examined, Parkin emerged as a key differentiator between the two groups.
 
Parkin is a protein well-known for its role in Parkinson's disease, where it is involved in mitochondrial function and the degradation of damaged mitochondria. Mitochondria are essential for cellular energy production, and their dysfunction is a hallmark of many neurodegenerative diseases, including Parkinson's.
 
The study team, led by Dr. Nadezhda G. Gumanova, Dr. Natalya L. Bogdanova, and Dr. Alexander Yu. Gorshkov, sought to examine whether there was a specific association between Parkin and COVID-19. This association could provide valuable insights into the potential neurological effects of the virus and offer a new perspective on how COVID-19 may influence neurodegenerative disorders.
 
Methodology
The research team collected serum samples from two groups of participants. Group 1, comprised of 208 participants, had their samples collected prior to the COVID-19 pandemic (2016-2018), while Group 2, consisting of 308 participants, provided samples during the pandemic (2019-2021). The participants were healthy individuals with no acute or chronic diseases at the time of sample collection.
 
The researchers used advanced antibody microarray technology to analyze the serum samples, focusing on the proteins that were differentially expressed between COVID-19-positive and COVID-19-negative individuals. The primary focus of the study was on identifying proteins that showed a clear distinction between these two groups.
 
Parkin was identified as a key protein of interest due to its significant elevation in the serum of COVID-19-positive patients compared to those who had not been infected by the virus. This finding prompted the researchers to further validate the results through an in-house enzyme-linked immunosorbent assay (ELISA) to ensure the accuracy of their findings.
 
Key Findings
The study revealed that patients who had recovered from COVID-19 exhibited significantly higher levels of Parkin in their blood compared to those who had never been infected. The average levels of Parkin were substantially elevated in the SARS-CoV-2-positive group, which suggests that COVID-19 might have a unique impact on the expression of this protein.
 
This elevated expression of Parkin is noteworthy because of the protein's involvement in the cellular process of mitophagy, where damaged mitochondria are targeted for degradation. In the context of neurodegenerative diseases, the proper functioning of this process is critical for preventing the accumulation of defective mitochondria, which can lead to the death of neurons.
 
The researchers also compared the levels of Parkin in individuals with adenovirus antibodies, a different viral infection, to assess whether the increase in Parkin levels was specific to COVID-19. Interestingly, the levels of Parkin in individuals who had been exposed to adenovirus did not show any significant differences compared to those who had not. This finding underscores the specificity of the Parkin increase to COVID-19, indicating that the virus may have a unique influence on mitochondrial function and cellular health.
 
Implications for Neurodegenerative Disease
The study's findings open the door to new research avenues regarding the relationship between COVID-19 and neurodegenerative diseases such as Parkinson's disease. The fact that Parkin, a protein so closely tied to neurodegeneration, is elevated in COVID-19-positive patients raises the possibility that the virus could contribute to or exacerbate existing neurological conditions.
 
The researchers hypothesize that the elevated levels of Parkin may be a response to the oxidative stress and inflammation caused by COVID-19. Oxidative stress, a condition in which harmful molecules known as free radicals accumulate in the body, can damage cells and tissues, including neurons in the brain. Inflammation, another key feature of viral infections, can also lead to long-term damage, particularly in the nervous system.
 
These processes - oxidative stress and inflammation - are known to play significant roles in the development of neurodegenerative diseases. The findings suggest that individuals recovering from COVID-19 may face an increased risk of developing conditions like Parkinson's disease in the future, especially if they already have underlying risk factors such as genetic predispositions or pre-existing neurodegenerative conditions.
 
Future Research Directions
The researchers plan to continue investigating the link between COVID-19 and neurodegenerative diseases by conducting longitudinal studies that follow patients over time. By tracking the long-term health outcomes of COVID-19 survivors, they aim to determine whether the elevated levels of Parkin and other proteins persist and whether they correlate with an increased risk of developing neurodegenerative diseases.
 
Additionally, further studies will focus on understanding the specific mechanisms through which COVID-19 affects mitochondrial function and how these effects contribute to the overall impact of the virus on the brain and nervous system.
 
Conclusion
In conclusion, this study has provided valuable insights into the molecular impact of COVID-19, particularly concerning the elevation of Parkin levels in the serum of infected individuals. The findings suggest that COVID-19 may have unique effects on mitochondrial function and oxidative stress, which could have long-term consequences for neurological health.
 
The association between Parkin and COVID-19, as demonstrated in this study, highlights the importance of further research into the potential link between viral infections and neurodegenerative diseases. While the study does not definitively prove that COVID-19 causes or accelerates conditions like Parkinson's disease, it provides strong evidence that the virus may contribute to the underlying mechanisms of these diseases.
 
The study findings were published on a preprint server and are currently being peer reviewed.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4972807
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/researchers-warn-that-sars-cov-2-is-triggering-neurodegenerative-diseases-like-parkinsons
 
https://www.thailandmedical.news/news/how-sars-cov-2-spike-protein-triggers-neurodegenerative-diseases-and-the-potential-of-metformin-as-a-therapeutic-remedy